Freeths advises SenzaGen on acquisition of UK life sciences company Alcyomics

Freeths has advised Swedish life sciences company SenzaGen AB on the UK legal aspects of its acquisition of Newcastle-based Alcyomics Ltd, strengthening the group’s position in the growing market for non-animal drug safety testing.

SenzaGen specialises in non-animal testing methods used to assess the safety of chemicals, cosmetics, medical devices and pharmaceuticals. The acquisition forms part of its long-term growth strategy and expands its offering within pharmaceutical drug development.

The initial purchase price for Alcyomics was approximately £2.12 million, with potential additional earn-out payments linked to future performance and net debt.

Alcyomics provides preclinical immunotoxicology testing services, with a focus on biological drugs used in areas including cancer treatment. Its proprietary Skimune® platform combines human skin tissue and immune cells to identify potential immune-related adverse effects during the preclinical phase of drug development.

The company works with pharmaceutical businesses across Europe, the US and Japan. It reported revenue growth of 46% in the 2025/26 financial year, generating revenue of approximately £1.49 million.

The acquisition will broaden SenzaGen’s capabilities in non-animal testing and give the group access to a new area of drug development, while strengthening its presence in the UK life sciences market. The two businesses also share expertise in immunology, creating opportunities across sales, business development and research and development.

Leading Freeths on this deal was Corporate Partner Claus Andersen, supported by Corporate Associates Rebecca Rudd and Alfie Rowland. Vinge was led by Christian Lindhé and advised on the Swedish legal aspects of the deal.

Claus Andersen said: “This transaction brings together two businesses with specialist expertise in immunology and a shared focus on alternatives to animal testing. We worked closely with SenzaGen and its wider adviser team to navigate the UK aspects of the transaction and support its expansion into an important area of drug development.”

Peter Nählstedt, President and CEO of SenzaGen, added: “The acquisition of Alcyomics strengthens our position in non-animal testing and expands our capabilities in pharmaceutical drug development. We appreciated Freeths’ support and their clear commercial advice throughout the transaction, which helped us navigate UK legal aspects. Claus and his team helped us complete an important strategic acquisition for the group.”

Get in touch

Contact us today

Whatever your legal needs, our wide ranging expertise is here to support you and your business, so let’s start your legal journey today and get you in touch with the right lawyer to get you started.

Telephone

Get in touch

For general enquiries, please complete this form and we will direct your message to the most appropriate person.